Molecular Subtyping for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma
NCT ID: NCT05483257
Last Updated: 2022-08-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
226 participants
OBSERVATIONAL
2018-03-14
2021-09-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma
NCT05479708
Prognostic Biomarkers of Pancreatic Cancer Based on Proteomics Techniques
NCT05088161
Prognostic Biomarkers of Pancreatic Cancer Based on Proteomic Techniques
NCT05289895
Integrative Proteomic Characterization of Pancreatic Ductal Adenocarcinoma
NCT04525209
Precise Gene Signature for Predicting Outcomes in PDAC
NCT05441189
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Multigene panel for next-generation sequencing
HLA-I genotyping based on next-generation sequencing for prognosis evaluation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Resected tumor tissues and matched blood cells available
* Signed informed consent
Exclusion Criteria
* Non-radical resection
34 Years
84 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GeneCast Biotechnology Co., Ltd.
INDUSTRY
BAIYONG SHEN
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
BAIYONG SHEN
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ruijin Hospital
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Wen C, Zhang L, Yang Y, Jin Y, Ren D, Zhang Z, Zou S, Li F, Sun H, Jin J, Lu X, Xie J, Cheng D, Xu Z, Chen H, Mao B, Zhang J, Wang J, Deng X, Peng C, Li H, Jiang C, Lin L, Zhang H, Chen H, Shen B, Zhan Q. Specific human leukocyte antigen class I genotypes predict prognosis in resected pancreatic adenocarcinoma: a retrospective cohort study. Int J Surg. 2023 Jul 1;109(7):1941-1952. doi: 10.1097/JS9.0000000000000264.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M-Cli200633-PC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.